We provide targeted DNA sequencing allowing us to focus specific areas of interest at a reduced price and faster delivery time. Our laboratory’s technology can accommodate small blood sample sizes, making it viable alternative to a trip to the phlebotomist and reducing the impact of blood-drawing on patients’ health.
NEXT GENERATION SEQUENCING – GERMLINE MUTATION
Our Obesity Amplicon Sequencing Panel targets 35 genes that were expertly selected based on their association with obesity. This assay is performed using genomic DNA isolated from human peripheral whole blood specimens.
The test is intended to identify the variants that are associated with obesity. It is performed as a pre-symptomatic genetic test in order to determine whether persons with a family history of obesity, but no current symptoms, has the gene alterations associated with the disease. The test can also be used for post-symptomatic genetic testing to confirm variants of association to obesity.
There is a direct correlation between increasing obesity and a higher risk of health problems such as type 2 diabetes, coronary heart disease, hypertension, arthritis, and even cancer. Unraveling the genetic background associated obesity may lead to more efficient ways to manage the obesity phenomenon and diseases associated with it.
All tests are performed in Ayass BioScience, LLC. Ayass BioScience, LLC (DBA Ayass Lung Clinic, PLLC) is a CLIA certified laboratory. If you have any questions about Genetic Testing Next Generation Sequencing at Ayass BioScience, LLC, please call today at 972-668-6005 or fill out our contact form on the bottom of this page. We will answer any question you might have.